Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - misoprostol, quantity: 25 microgram - tablet, uncoated - excipient ingredients: hypromellose; microcrystalline cellulose; maize starch; croscarmellose sodium; crospovidone; colloidal anhydrous silica - angusta is indicated for induction of labour.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - rifaximin, quantity: 550 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; titanium dioxide; glyceryl diisostearate; purified talc; hypromellose; propylene glycol; disodium edetate; colloidal anhydrous silica; iron oxide red; sodium starch glycollate type a - prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - ascorbic acid, quantity: 7.54 g; sodium ascorbate, quantity: 48.11 g - solution, powder for - excipient ingredients: - bowel cleansing prior to any procedure requiring a clean bowel.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - sodium sulfate, quantity: 7.5 g; macrogol 3350, quantity: 100 g; potassium chloride, quantity: 1.015 g; ascorbic acid, quantity: 4.7 g; sodium ascorbate, quantity: 5.9 g; sodium chloride, quantity: 2.691 g - powder - excipient ingredients: acesulfame potassium; aspartame; flavour - for bowel cleansing prior to any clinical procedure requiring a clean bowel e.g. bowel endoscopy, lower gastrointestinal tract radiology or digestive tract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - ascorbic acid, quantity: 4.7 g; macrogol 3350, quantity: 100 g; sodium ascorbate, quantity: 5.9 g; potassium chloride, quantity: 1.015 g; sodium sulfate, quantity: 7.5 g; sodium chloride, quantity: 2.691 g - powder - excipient ingredients: acesulfame potassium; aspartame; flavour - for bowel cleansing prior to any clinical procedure requiring a clean bowel e.g. bowel endoscopy, lower gastrointestinal tract radiology or digestive tract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - rifaximin, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; glyceryl isostearate; sodium starch glycollate type a; colloidal anhydrous silica; purified talc; hypromellose; titanium dioxide; disodium edetate; propylene glycol; iron oxide red - xifaxan is indicated for the treatment of patients ( > = 12 years of age) with travellers? diarrhoea caused by non-invasive strains of escherichia coli (see ?precautions?, and ?clinical trials? ). travellers? diarrhoea describes a clinical picture predominantly observed in subjects travelling from developed to developing countries. it is most frequently caused by enterotoxigenic escherichia coli (etec), enteroaggregative e. coli (eaec) and other non-invasive pathogens.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - rifaximin -

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - 63185 - cognitive assessment software - liversync is an application to help monitor changes in the neurophysiological status/condition of non-hospitalised liver cirrhosis patients at risk of developing hepatic encephalopathy; it provides the patient with cognitive tests on a mobile device and the results are captured, assisting hcps to determine whether intervention is required.

Australia - English - Department of Health (Therapeutic Goods Administration)

hl pharma pty ltd - tilmanocept, quantity: 50 microgram - injection, powder for - excipient ingredients: sodium ascorbate; sodium hydroxide; trehalose dihydrate; hydrochloric acid; stannous chloride dihydrate; glycine - this medicinal product is for diagnostic use only. radiolabelled lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity. external imaging and intraoperative evaluation may be performed using a gamma detection device.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd -